Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin

Pharmaceutical Research

Volumn 16, Issue 9, 1999, Pages 1386-1391

  Gysler, Anja ^a   Kleuser, Burkhard ^a   Sippl, Wolfgang ^b   Lange, Katharina ^a   Korting, Hans Christian ^c   Höltje, Hans Dieter ^b   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Benefit risk ratio; Drug metabolism; Prednicarbate; Skin penetration; Topical glucocorticoids

Indexed keywords

BETAMETHASONE VALERATE; GLUCOCORTICOID; PREDNICARBATE; RECEPTOR;

ARTICLE; DRUG METABOLISM; EPIDERMIS; FIBROBLAST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SKIN; SKIN PENETRATION; STRATUM CORNEUM; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE 17-VALERATE; CELLS, CULTURED; EPIDERMIS; ESTERASES; FEMALE; FIBROBLASTS; GLUCOCORTICOIDS; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; OINTMENTS; PREDNISOLONE; RISK ASSESSMENT; SKIN ABSORPTION;

EID: 0032872437     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018946924585     Document Type: Article

References (21)

1. M. Schäfer-Korting, H. C. Korting, M. J. Kerscher, and S. Lenhard. Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin. Pharmacol. Ther. 54:448-456 (1993).
2. N. Bodor. The application of soft drug approaches to the design of safer corticosteroids. In E. Christophers, E. Schöpf, A. M. Kligman, and R. B. Stoughton (eds.), Topical Corticosteroid Therapy-A Novel Approach to Safer Drugs, Raven Press, New York, 1988, pp. 13-25.
3. A. Gysler, K. Lange, H. C. Korting, and M. Schäfer-Korting. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm. Res. 14:793-97 (1997).
4. K. Lange, A. Gysler, B. Kleuser, M. Bader, H. C. Korting, and M. Schäfer-Korting. Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in-vitro. Pharm Res. 14:7744-1749 (1997).
5. S. W. Collier, N. M. Sheikh, A. Sakr, J. L. Lichtin, R. F. Stewart, and R. L. Bronaugh. Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies. Toxicol. Appl. Pharmacol. 99:522-533 (1989).
6. O. H. Lowry, N. J. Rosenbrough, A. Lewis Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
7. P. K. Smith, R. I. Krohn, G. T. Hermanson, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. Measurement of protein using bicinchonic acid. Anal. Biochem. 150:76-85 (1985).
8. H.-D. Höltje and G. Folkers. Molecular Modelling-Basic Principles and Applications, VCH Publisher, New York, 1996.
9. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, and J. J. P. Stewart, AMI: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107:3902-3909 (1985).
10. C. J. Cramer and D. G. Truhlar. General parameterized SCF model for free energies of solvation in aqueous solution. J. Am. Chem. Soc. 113:8305-8311 (1991).
11. W. S. Watson and A. Y. Finlay. The effect of the vehicle formulation on the stratum corneum penetration characteristics of clobetasol propionate in vivo. Br. J. Dermatol. 118:523-527 (1988).
12. H. C. Korting, D. Vieluf, and M. Kerscher. 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone 17-valerate cream and 0.05% clobetasol 17-propionate cream. Eur. J. Clin. Pharmacol. 42:159-161 (1992).
13. A. M. Kligman. Skin permeability: Dermatologic aspects of transdermal drug delivery. Am. Heart J. 108:200-206 (1984).
14. A. Rougier, D. Dupuis, C. Lotte, R. Roguet, and H. Schaefer. In vivo correlation between stratum corneum reservoir function and percutaneous absorption. J. Invest. Dermatol. 81:275-278 (1983).
15. U. Täuber and K. L. Rost. Esterase activity of the skin including species variations. In B. Shroot and H. Schaefer (eds.), Pharmacology and the Skin, Karger, Basel, 1987, pp. 170-183.
16. M. Pörtner, H. Möllmann, and P. Rohdewald, Glucocorticoid receptors in human synovial tissue and relative receptor affinities of glucocorticoid-21-esters. Pharm. Res. 10:623-627 (1988).
17. G. Würthwein, S. Rehder, and P. Rohdewald. Lipophilicity and receptor affinity of glucocorticoids. Pharm. Ztg. Wiss. 4:161-167 (1992).
18. J. Levy, J. Gassmüller, G. Schröder, H. Audring, and N. Sönnichsen. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. Skin Pharmacol. 7:231-236 (1994).
19. 2 ZK 1350 to phototoxicity and skin corrosivity testing. Toxicol. in Vitro 9:557-562 (1995).
20. G. E. Pièrard, V. Goffin, T. Herrmanns-Le, J. Arrese, and C. Pièrard-Franchimont. Surfactant-induced dermatitis: Comparison of corneosurfametry with predictive testing on human and reconstructed skin. J. Am. Acad. Dermatol. 33:462-469 (1995).
21. A. Gysler, U. Bacher, and M. Schäfer-Korting. Penetration und Metabolisierung von Glucocorticoiden bei Hautäquivalenten und exzidierter Humanhaut. In H. Schöffl, H. Spielmann, and H. A. Tritthart (eds.), Do it in Vitro, Springer Verlag, Wien, New York, in press.